Literature DB >> 11805138

Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity.

Arno Hänninen1, Nathan R Martinez, Gayle M Davey, William R Heath, Leonard C Harrison.   

Abstract

Antigen administration via oral and other mucosal routes can suppress systemic immunity to the antigen and has been used to prevent experimental autoimmune disease. This approach may prove ineffective or even harmful if it leads to a concomitant induction of cytotoxic T lymphocytes (CTLs), and indeed, mucosal administration of the model antigen ovalbumin (OVA) has been shown to elicit CTL activation while simultaneously inducing oral tolerance. Here we show that induction by oral OVA of CTLs in wild-type mice, and of diabetes in mice expressing OVA transgenically in pancreatic beta cells, can be prevented by transiently blocking the CD40 ligand (CD40L). However, CD40L blockade did not diminish oral tolerance, as measured by suppression of systemic OVA-primed T cell proliferation, IFN-gamma secretion, and Ab production. Consistent with these findings, mice lacking CD40 expression could be orally tolerized to OVA. Transient CD40L blockade therefore dissociates pathogenic from protective immunity and should enhance the efficacy and safety of oral tolerance for preventing autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805138      PMCID: PMC150838          DOI: 10.1172/JCI13720

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Authors:  S P Schoenberger; R E Toes; E I van der Voort; R Offringa; C J Melief
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

2.  Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.

Authors:  M J Barnden; J Allison; W R Heath; F R Carbone
Journal:  Immunol Cell Biol       Date:  1998-02       Impact factor: 5.126

3.  DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity.

Authors:  J S Boyle; A Silva; J L Brady; A M Lew
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

4.  Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis.

Authors:  K M McKown; L D Carbone; S B Kaplan; J A Aelion; K M Lohr; M A Cremer; J Bustillo; M Gonzalez; G Kaeley; E L Steere; G W Somes; L K Myers; J M Seyer; A H Kang; A E Postlethwaite
Journal:  Arthritis Rheum       Date:  1999-06

5.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

Authors:  S R Bennett; F R Carbone; F Karamalis; R A Flavell; J F Miller; W R Heath
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

6.  Mucosally induced systemic T cell unresponsiveness to ovalbumin requires CD40 ligand-CD40 interactions.

Authors:  M N Kweon; K Fujihashi; Y Wakatsuki; T Koga; M Yamamoto; J R McGhee; H Kiyono
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

7.  Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats.

Authors:  K Bellmann; H Kolb; S Rastegar; P Jee; F W Scott
Journal:  Diabetologia       Date:  1998-07       Impact factor: 10.122

8.  TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation.

Authors:  M F Bachmann; B R Wong; R Josien; R M Steinman; A Oxenius; Y Choi
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

9.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

10.  Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction.

Authors:  C Kurts; J F Miller; R M Subramaniam; F R Carbone; W R Heath
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  13 in total

Review 1.  CD40L in autoimmunity and mucosally induced tolerance.

Authors:  Mi-Na Kweon; Hiroshi Kiyono
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Amelia Fernandez-Martin; Doina Ganea; Mario Delgado
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

Review 3.  Strategies of mucosal immunotherapy for allergic diseases.

Authors:  Yi-Ling Ye; Ya-Hui Chuang; Bor-Luen Chiang
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

Review 4.  Antigen-based vaccination and prevention of type 1 diabetes.

Authors:  Leonard C Harrison; John M Wentworth; Yuxia Zhang; Esther Bandala-Sanchez; Ralph M Böhmer; Alana M Neale; Natalie L Stone; Gaetano Naselli; Julian J Bosco; Priscilla Auyeung; Maryam Rashidi; Petra Augstein; Grant Morahan
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

5.  CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes.

Authors:  Gisela M Vaitaitis; Dan M Waid; Martin G Yussman; David H Wagner
Journal:  Immunology       Date:  2017-06-19       Impact factor: 7.397

6.  Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

Authors:  Nathan R Martinez; Petra Augstein; Antonis K Moustakas; George K Papadopoulos; Silvia Gregori; Luciano Adorini; David C Jackson; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?

Authors:  Arno Hanninen; Leonard C Harrison
Journal:  Rev Diabet Stud       Date:  2004-11-10

8.  Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells.

Authors:  Susan Johnson; Yifan Zhan; Robyn M Sutherland; Adele M Mount; Sammy Bedoui; Jamie L Brady; Emma M Carrington; Lorena E Brown; Gabrielle T Belz; William R Heath; Andrew M Lew
Journal:  Immunity       Date:  2009-02-05       Impact factor: 31.745

9.  Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection.

Authors:  Rodolfo D Vicetti Miguel; Robert L Hendricks; Alfredo J Aguirre; Melissa A Melan; Stephen A K Harvey; Tracy Terry-Allison; Anthony J St Leger; Angus W Thomson; Thomas L Cherpes
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

Review 10.  Mucosal exposure to antigen: cause or cure of type 1 diabetes?

Authors:  Georgia Fousteri; Matthias von Herrath; Damien Bresson
Journal:  Curr Diab Rep       Date:  2007-04       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.